Indicated for patients with a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, the drug could be used in around 13% of the disease population. Sarepta’s share price almost ...

whose mutations are amenable to an exon 51-skipping approach. In the ongoing CO If you are looking for stocks that are well positioned to maintain their recent uptrend, PepGen (PEPG) could be a ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

was the first treatment approved in the US in 2016 as an injection indicated for patients with confirmed mutation of dystrophin gene amenable to exon 51 skipping. PTC Therapeutics’ Translarna ...

Entrada Therapeutics announced it has been cleared in the U.K. to start a Phase 1/2 clinical trial of ENTR-601-44, at increasing doses, in Duchenne muscular dystrophy (DMD) patients with a mutation in ...

It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the ...

Last week, President Trump signed into law the Laken Riley Act, which requires the attorney general to detain any non-citizen charged with theft or shoplifting, among other offenses. While doing ...

Treatment with oral therapy ifetroban led to improvements in measures of heart function in people with Duchenne muscular dystrophy (DMD), according to top-line results from a clinical trial. The ...

Our best budget pick is the DEGOL Skipping Rope with its PVC-covered wire, which makes the rope stiffer, and great for durability, speed and storage. According to the National Library of Medicine ...